New device promises reliable rehabilitation for balance disorders

The University of the Basque Country (UPV/EHU) has presented a promising device designed to conduct measurements reliably and repeatably when treating the after-effects of stroke, vertigo, etc.

New peptide library paves the way for targeting elusive cancer factor MYC

Researchers developed a second-generation NTB bicyclic peptide library, identifying NT-B2R, a peptide that effectively targets MYC, a key factor in most human cancers, demonstrating its

January 8, 2024

Major studies reveal improved treatment for children with Group 3 medulloblastoma

Vital research findings pointing to improved treatment for children with Group 3 medulloblastoma brain tumors have been revealed in two major studies published in the

October 9, 2024

J&J’s Spravato receives FDA label expansion for depression monotherapy – Pharmaceutical Technology

Major depressive disorder (MDD) is characterised by characterised by depression and inability to feel pleasure. Credit: Justin Paget via Getty Images. Johnson & Johnson’s (J&J)

January 22, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.